Tricuspid Regurgitation Device Passes in Pivotal Trial

(MedPage Today) -- SAN FRANCISCO -- Tricuspid valve regurgitation treated with the investigational JenaValve Trilogy appeared safe and effective in the ALIGN AR trial. The device met the safety benchmark, with a 26.7% rate of combined 30-day...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news